Cannabis use and cannabis use disorder
Cannabis use disorder (CUD) is an underappreciated risk of using cannabis that affects~
10% of the 193 million cannabis users worldwide. The individual and public health burdens …
10% of the 193 million cannabis users worldwide. The individual and public health burdens …
Association of cannabis potency with mental ill health and addiction: a systematic review
Cannabis potency, defined as the concentration of Δ 9-tetrahydrocannabinol (THC), has
increased internationally, which could increase the risk of adverse health outcomes for …
increased internationally, which could increase the risk of adverse health outcomes for …
Changes in delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta‐analysis
Background and aims Cannabis products with high delta‐9‐tetrahydrocannabinol (THC)
concentrations carry an increased risk of addiction and mental health disorders, while it has …
concentrations carry an increased risk of addiction and mental health disorders, while it has …
Dopamine and addiction
RA Wise, MA Robble - Annual review of psychology, 2020 - annualreviews.org
Addiction is commonly identified with habitual nonmedical self-administration of drugs. It is
usually defined by characteristics of intoxication or by characteristics of withdrawal …
usually defined by characteristics of intoxication or by characteristics of withdrawal …
New trends in cannabis potency in USA and Europe during the last decade (2008–2017)
Through the potency monitoring program at the University of Mississippi supported by
National Institute on Drug Abuse (NIDA), a total of 18108 samples of cannabis preparations …
National Institute on Drug Abuse (NIDA), a total of 18108 samples of cannabis preparations …
[HTML][HTML] Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations …
Background Cannabis use is common, especially among young people, and is associated
with risks for various health harms. Some jurisdictions have recently moved to …
with risks for various health harms. Some jurisdictions have recently moved to …
[HTML][HTML] Medicinal cannabis: history, pharmacology, and implications for the acute care setting
MB Bridgeman, DT Abazia - Pharmacy and therapeutics, 2017 - ncbi.nlm.nih.gov
Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting - PMC
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
Background A substantial and unmet clinical need exists for pharmacological treatment of
cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which …
cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which …
Cannabis addiction and the brain: a review
Cannabis is the most commonly used substance of abuse in the United States after alcohol
and tobacco. With a recent increase in the rates of cannabis use disorder (CUD) and a …
and tobacco. With a recent increase in the rates of cannabis use disorder (CUD) and a …
[HTML][HTML] The neuropsychopharmacology of cannabis: A review of human imaging studies
The laws governing cannabis are evolving worldwide and associated with changing
patterns of use. The main psychoactive drug in cannabis is Δ 9-tetrahydrocannabinol (THC) …
patterns of use. The main psychoactive drug in cannabis is Δ 9-tetrahydrocannabinol (THC) …